Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: Correlation between Androgen Receptor Expression and Pathological Response

Mohammed, Amrallah A.; Elsayed, Fifi Mostafa; Algazar, Mohammed; Rashed, Hayam E.; Anter, Abeer Hussien

doi:10.31557/apjcp.2020.21.2.563

Cited by 21 publications

(17 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hence, knowledge about differences between TNBCs in the young and the elderly could lighten the differences in therapeutic approach, as older patients could be less responsive to conventional chemotherapy and might benefit more from a more personalized therapeutic approach (e.g., anti-androgen therapy) [ 33 ]. Even though AR-positive tumors appeared more often in postmenopausal patients [ 26 , 34 , 35 ] and a higher percentage of postmenopausal women was found in the LAR subtype [ 36 ], there was no significant correlation between AR and menopausal status found [ 31 , 37 , 38 ].…”

Section: Clinical Characteristics Of Ar-positive Tnbcmentioning

confidence: 99%

“…Ki-67 was lower among the LAR subtype than in the other subtypes [ 4 , 44 , 45 ]. Similarly, AR-positive tumors were more likely to have lower Ki-67 [ 28 , 31 , 34 , 35 , 46 , 47 ] which could be due to anti-proliferative effect of AR stimulation [ 46 ], suggesting a protective role or better biological fundament with expression of AR [ 47 ]. On the contrary, AR expression was not associated with Ki-67 [ 38 ].…”

Section: Clinical Characteristics Of Ar-positive Tnbcmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Implications of Androgen-Positive Triple-Negative Breast Cancer

Brumec

Sobočan

Takač

et al. 2021

Cancers

View full text Add to dashboard Cite

This review summarizes the recent findings of a vast array of studies conducted on androgen receptor-positive triple-negative breast cancer (AR-positive TNBC) to provide a better understanding of this specific breast cancer subgroup. AR expression is correlated with higher age, lower histological grade, lower proliferation index Ki-67, spiculated masses, and calcifications on mammography. Studies investigating the correlation between AR expression and lymph node metastasis are highly discordant. In addition, results regarding prognosis are highly contradictory. AR antagonists are a promising novel therapeutic approach in AR-positive TNBC. However, AR signaling pathways should be more investigated in order to understand the influence of AR expression on TNBC more thoroughly.

show abstract

Section: Clinical Characteristics Of Ar-positive Tnbcmentioning

confidence: 99%

Section: Clinical Characteristics Of Ar-positive Tnbcmentioning

confidence: 99%

Clinical Implications of Androgen-Positive Triple-Negative Breast Cancer

Brumec

Sobočan

Takač

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Studies show that AR can probably predict neoadjuvant treatment effects. AR expression seemed to be related to a lower pCR rate and worse outcome in TNBC [3,[17][18][19][20], but there was also controversy related to these results [21]. In HER2 positive breast cancer, AR+ positivity was associated with pCR, but in this study, only 57.3% of patients received trastuzumab [15].…”

Section: Introductionmentioning

confidence: 80%

“…AR expression has been suggested to predict the response to neoadjuvant therapy in the literature. AR-negative TNBC patients had higher pCR rates than AR-positive TNBC patients [3,[18][19][20]. In these studies, researchers often adopted 1% or 10% as the cutoff of AR.…”

Section: Discussionmentioning

confidence: 99%

Androgen Receptor: A New Marker to Predict Pathological Complete Response in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Plus Pertuzumab Neoadjuvant Therapy

Zhang

Wang

et al. 2022

JPM

View full text Add to dashboard Cite

(1) Background: Neoadjuvant therapy is the main therapeutic strategy for human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients, and the combination of trastuzumab and pertuzumab (HP) has become a routine treatment. How to predict and screen patients who are less likely to respond to neoadjuvant therapy is the focus of research. The androgen receptor (AR) is a biomarker that is widely expressed in all breast cancer subtypes and is probably related to treatment response and prognosis. In this study, we investigated the relationship between AR expression and treatment response in HER2-positive breast cancer patients treated with HP neoadjuvant therapy. (2) Methods: We evaluated early breast cancer patients treated with HP neoadjuvant therapy from Jan. 2019 to Oct. 2020 at Peking University First Hospital Breast Cancer Center. The inclusion criteria were as follows: early HER2-positive breast cancer patients diagnosed by core needle biopsy who underwent both HP neoadjuvant therapy and surgery. We compared the clinical and pathological features between pathological complete response (pCR) and non-pCR patients. (3) Results: We included 44 patients. A total of 90.9% of patients received neoadjuvant therapy of taxanes, carboplatin, trastuzumab and pertuzumab (TCHP), and the total pCR rate was 50%. pCR was negatively related to estrogen receptor (ER) positivity (OR 0.075 [95% confidence interval (CI) 0.008–0.678], p = 0.021) and positively related to high expression levels of AR (OR 33.145 [95% CI 2.803–391.900], p = 0.005). We drew a receiver operating characteristic (ROC) curve to assess the predictive value of AR expression for pCR, and the area under the curve was 0.737 (95% CI 0.585–0.889, p = 0.007). The optimal cutoff of AR for predicting pCR was 85%. (4) Conclusion: AR is a potential marker for the prediction of pCR in HER2-positive breast cancer patients treated with HP neoadjuvant therapy.

show abstract

“…Several studies have evaluated post-NAC results based on HER2-positive or triple-negative breast cancer status [8][9][10]. Some studies have indicated that axillary pCR is associated with a biological subtype, initial clinical tumor stage, clinical nodal stage, and breast pCR [4].…”

Section: Discussionmentioning

confidence: 99%

Factors Affecting Pathologic Complete Remission in Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy

et al. 2022

View full text Add to dashboard Cite

Introduction: Pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) is associated with improvement in survival outcomes. This study evaluated the pCR in patients with hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer after NAC. Methods: We evaluated 417 patients who were diagnosed with invasive breast cancer and treated with NAC followed by curative surgery between January 2007 and December 2020 and analyzed the pCR for HR-positive and HER2-negative breast cancer. Results: The median age at the time of surgery was 45.4 years, and 9.1% of patients (38 of 417) with HR-positive/HER2-negative status had pCR. Among patients with HR-positive/HER2-negative breast cancer, patients with single HR-positivity had a 20.2% pCR rate, and patients with double HR-positivity had a 4.4% pCR rate. Patients with a high Ki-67 index exhibited a higher pCR rate than those with a lower Ki-67 index (14.5% vs. 3.2%). Patients with single HR-positive and high Ki-67 values exhibited a significantly higher pCR rate than those with double HR-positive and low Ki-67 values (27.8% vs. 2.1%; p < 0.001). Conclusion: NAC could improve prognosis in patients with HR-positive/HER2-negative breast cancer with a single HR-positive and high Ki-67 values.

show abstract

Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: Correlation between Androgen Receptor Expression and Pathological Response

Cited by 21 publications

References 28 publications

Clinical Implications of Androgen-Positive Triple-Negative Breast Cancer

Clinical Implications of Androgen-Positive Triple-Negative Breast Cancer

Androgen Receptor: A New Marker to Predict Pathological Complete Response in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Plus Pertuzumab Neoadjuvant Therapy

Factors Affecting Pathologic Complete Remission in Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy

Contact Info

Product

Resources

About